Literature DB >> 20111632

Defining efficacy in the treatment of overactive bladder syndrome.

Sagar Shah1, Victor W Nitti.   

Abstract

Patients seek treatment for overactive bladder syndrome (OAB) due to poor quality of life, and perceived improvement in quality of life (QOL) from medical therapy is multifactorial. Many feel that efficacy/success of medical therapy for OAB should not be linked to improvements in 1 or 2 endpoints, but instead should be linked to patient expectation and QOL improvement. Ideally, once patient-centered goals are defined, outcomes should be correlated with relief of symptom(s), patient satisfaction, and goal attainment expectations as a result of treatment.

Entities:  

Keywords:  Medical therapy for OAB; Overactive bladder syndrome; Patient-centered treatment

Year:  2009        PMID: 20111632      PMCID: PMC2809987     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  37 in total

1.  Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.

Authors:  Yanni F Yu; Michael B Nichol; Andrew P Yu; Jeonghoon Ahn
Journal:  Value Health       Date:  2005 Jul-Aug       Impact factor: 5.725

2.  Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.

Authors:  Con J Kelleher; Linda Cardozo; Christopher R Chapple; Francois Haab; Arwin M Ridder
Journal:  BJU Int       Date:  2005-01       Impact factor: 5.588

3.  Assessment of satisfaction with treatment for chronic pain.

Authors:  L M McCracken; P A Klock; D J Mingay; J K Asbury; D M Sinclair
Journal:  J Pain Symptom Manage       Date:  1997-11       Impact factor: 3.612

4.  Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.

Authors:  Peter Dwyer; Con Kelleher; Jay Young; François Haab; Karine Lheritier; Rinat Ariely; Ursula Ebinger
Journal:  Neurourol Urodyn       Date:  2008       Impact factor: 2.696

5.  Impact of fesoterodine on quality of life: pooled data from two randomized trials.

Authors:  Con J Kelleher; Andrea Tubaro; Joseph T Wang; Zoe Kopp
Journal:  BJU Int       Date:  2008-07       Impact factor: 5.588

6.  Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.

Authors:  Roger R Dmochowski; Peter K Sand; Norman R Zinner; Marc C Gittelman; G Willy Davila; Steven W Sanders
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

7.  Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.

Authors:  Anna O D'Souza; Michael J Smith; Lesley-Ann Miller; Joseph Doyle; Rinat Ariely
Journal:  J Manag Care Pharm       Date:  2008-04

8.  Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

Authors:  Kenneth Rockwood; Sherri Fay; Xiaowei Song; Chris MacKnight; Mary Gorman
Journal:  CMAJ       Date:  2006-03-22       Impact factor: 8.262

9.  Costs of urinary incontinence and overactive bladder in the United States: a comparative study.

Authors:  Teh-Wei Hu; Todd H Wagner; Judith D Bentkover; Kristi Leblanc; Steve Z Zhou; Timothy Hunt
Journal:  Urology       Date:  2004-03       Impact factor: 2.649

10.  Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.

Authors:  J J Wyndaele; E R Goldfischer; J D Morrow; J Gong; L J Tseng; Z Guan; M S Choo
Journal:  Int J Clin Pract       Date:  2009-04       Impact factor: 2.503

View more
  8 in total

Review 1.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

2.  Overactive bladder after female genital mutilation/cutting (FGM/C) type III.

Authors:  Jasmine Abdulcadir; Patrick Dällenbach
Journal:  BMJ Case Rep       Date:  2013-10-04

3.  European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder.

Authors:  Vik Khullar; Daniela Marschall-Kehrel; Montserrat Espuna-Pons; Con J Kelleher; Shannon E Tully; Elisabeth C Piault; Linda Brubaker; Aino Fianu-Jonasson; David Weinstein; Agneta Bergqvist; Marion Kvasz
Journal:  Int Urogynecol J       Date:  2013-04-09       Impact factor: 2.894

4.  A qualitative inquiry of patient-reported outcomes: the case of lower urinary tract symptoms.

Authors:  Lisa C Welch; Elizabeth M Botelho; Jean Journel Joseph; Sharon L Tennstedt
Journal:  Nurs Res       Date:  2012 Jul-Aug       Impact factor: 2.381

5.  The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.

Authors:  D Castro-Diaz; C R Chapple; Z Hakimi; M B Blauwet; L Delgado-Herrera; W Lau; S Mujais
Journal:  Qual Life Res       Date:  2015-02-17       Impact factor: 4.147

6.  A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).

Authors:  David Staskin; Sender Herschorn; Jonathan Fialkov; Le Mai Tu; Terry Walsh; Carol R Schermer
Journal:  Int Urogynecol J       Date:  2017-06-15       Impact factor: 2.894

7.  Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).

Authors:  Sender Herschorn; David Staskin; Le Mai Tu; Jonathan Fialkov; Terry Walsh; Katherine Gooch; Carol R Schermer
Journal:  Health Qual Life Outcomes       Date:  2018-04-19       Impact factor: 3.186

8.  Updating the evidence on drugs to treat overactive bladder: a systematic review.

Authors:  Frances C Hsu; Chandler E Weeks; Shelley S Selph; Ian Blazina; Rebecca S Holmes; Marian S McDonagh
Journal:  Int Urogynecol J       Date:  2019-07-25       Impact factor: 2.894

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.